Friday 6 November 2026
Export GKOS’s income statement to Excel — free account
Glaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
224.21
4.23
+1.92%
Follow GKOS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 4 | 5 |
| (26.38%) | (26.39%) | (25.98%) | (22.84%) | ||
| (20.09%) | (20.36%) | (19.72%) | (17.16%) | ||
ROIC |
(28.00%) | (26.89%) | (26.07%) | (24.60%) | |
Return on Tangible Assets |
(38.54%) | (37.21%) | (35.78%) | (30.05%) | |
Average Days of Receivables |
78.12 | 79.24 | 82.73 | 79.31 | |
Free Cash Flow per Share |
(0.68) | (0.60) | (0.21) | 0.61 | |
Free Cash Flow |
(39.06) | (35.09) | (12.20) | 36.02 | |
Capital Expenditures |
(24.27) | (26.29) | (11.25) | (11.69) | |
| Other line items | |||||
Cash ROIC |
(3.89%) | (3.46%) | (1.18%) | 3.21% | |
Accounts Receivable Turnover |
5.99 | 5.77 | 5.52 | 5.55 | |
Accounts Payable Turnover |
5.94 | 6.91 | 7.80 | 5.88 | |
Inventory Turnover |
1.84 | 1.98 | 2.07 | 2.09 | |
Average Days of Payables |
80.38 | 57.85 | 54.59 | 68.37 | |
Days of Inventory on Hand |
207.50 | 188.44 | 169.17 | 170.98 | |
Tax Rate |
(0.03) | (0.03) | (0.02) | (0.03) | |
Research and Development Expense of Revenue |
29.68% | 29.46% | 29.15% | 27.33% | |
Selling, General and Administrative Expense of Revenue |
65.38% | 64.21% | 63.10% | 62.96% | |
Share Based Compensation of Revenue |
12.46% | 12.58% | 13.09% | 12.04% | |
Interest Coverage |
(43.06) | (43.24) | (39.42) | (36.57) | |
Operating CF/Net income |
0.08 | 0.05 | 0.01 | (0.28) | |
Depreciation/Fixed assets |
0.35 | 0.39 | 0.40 | 0.40 | |
Capex/Depreciation |
(0.62) | (0.60) | (0.25) | (0.26) | |
Revenue per Share |
8.87 | 9.50 | 10.42 | 11.68 | |
Operating CF per Share |
(0.26) | (0.15) | (0.02) | 0.81 | |
Capex per Share |
(0.42) | (0.45) | (0.19) | (0.20) | |
Capex to Sales |
0.05 | 0.05 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026